To explore the potential roles of the 5mCscore in clinical immune therapy of lung cancer, we investigated whether the 5mCscore could predict patients’ response to PD-L1 (atezolizumab) therapy based on the PD-L1 immunotherapy cohort (IMvigor210). Here, CD274 is linked to lung carcinoma.